SciBase expands collaboration with Castle Biosciences, secures SEK 5 million study order
CSTL•SciBase secured an additional order worth approximately SEK 5 million from Castle Biosciences in the third quarter of 2026 to support a clinical study. A new NIH-led study will also use Nevisense to assess environmental exposure.
1. Additional study order
SciBase expanded its collaboration with Castle Biosciences during the third quarter of 2026, securing an additional order worth approximately SEK 5 million to support a clinical study. After the quarter, a new NIH-led study with the Swiss Institute of Allergy and Asthma Research will use Nevisense to assess environmental exposure.
